Cargando…
iPAPP: study protocol for a multicentre randomised controlled trial comparing safety and efficacy of intravenous paracetamol and indomethacin for the treatment of patent ductus arteriosus in preterm infants
INTRODUCTION: Patent ductus arteriosus (PDA) causes severe morbidity in premature infants. Although the use of indomethacin is the standard therapy for PDA, it is sometimes not applicable because of its adverse effects, such as renal and platelet dysfunctions. Paracetamol has emerged as an alternati...
Autores principales: | Namba, Fumihiko, Honda, Masakazu, Sakatani, Shun, Motojima, Yukiko, Kikuchi, Kayoko, Sako, Mayumi, Ogawa, Kunio, Mikami, Masashi, Kawada, Kou, Fukuoka, Noriyasu, Ueda, Keiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039996/ https://www.ncbi.nlm.nih.gov/pubmed/36958775 http://dx.doi.org/10.1136/bmjopen-2022-069314 |
Ejemplares similares
-
Safety and Feasibility of Intravenous Paracetamol for Patent Ductus Arteriosus in Indomethacin-/Ibuprofen-Resistant or -Contraindicated Preterm Infants: A Case Series
por: Oshima, Ayumi, et al.
Publicado: (2020) -
Low-Dose Intravenous Paracetamol for Patent Ductus Arteriosus in Indomethacin-Resistant or Contraindicated Preterm Infants: Three Cases Reports
por: Matsumura, Shun, et al.
Publicado: (2017) -
Early PARacetamol (EPAR) trial: a study protocol for a randomised controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants
por: Schindler, Tim, et al.
Publicado: (2019) -
Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe?
por: Bardanzellu, Flaminia, et al.
Publicado: (2017) -
Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates
por: Terrin, Gianluca, et al.
Publicado: (2014)